Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.43 |
| ▸ | DHODH | Q02127 | 4/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22172331 | 0.90 | MAP4K4 (0.45) | TGFBR1MAP4K4DHODHPI4K2API4KB | |
| SCHEMBL30721853 | 0.90 | MAP4K4 (0.45) | TGFBR1MAP4K4DHODHPI4K2API4KB | |
| SCHEMBL22163836 | 0.89 | MAP4K4 (0.53) | TGFBR1MAP4K4DHODHPI4K2API4KB | |
| SCHEMBL30721838 | 0.89 | MAP4K4 (0.53) | TGFBR1MAP4K4DHODHPI4K2API4KB | |
| SCHEMBL22172381 | 0.87 | MAP4K4 (0.51) | TGFBR1MAP4K4DHODHPI4K2API4KB | |
| SCHEMBL30721843 | 0.87 | MAP4K4 (0.51) | TGFBR1MAP4K4DHODHPI4K2API4KB | |
| SCHEMBL22172380 | 0.87 | MAP4K4 (0.46) | TGFBR1MAP4K4PI4K2API4KB | |
| SCHEMBL30721854 | 0.87 | MAP4K4 (0.46) | TGFBR1MAP4K4PI4K2API4KB | |
| SCHEMBL22172332 | 0.82 | MAP4K4 (0.45) | TGFBR1MAP4K4DHODHDHFRALKBH5 | |
| SCHEMBL30721822 | 0.82 | MAP4K4 (0.45) | TGFBR1MAP4K4DHODHDHFRALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017483-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN-KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD (CN) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017483-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | ADORA1, ADORA2A, ADORA2B | TGFBR1 2728/4885MAP4K4 4027/4885DHODH 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.